539 related articles for article (PubMed ID: 33950515)
1. The impact of socioeconomic status on stage at presentation, receipt of diagnostic imaging, receipt of treatment and overall survival in colorectal cancer patients.
Shah R; Chan KKW
Int J Cancer; 2021 Sep; 149(5):1031-1043. PubMed ID: 33950515
[TBL] [Abstract][Full Text] [Related]
2. Socioeconomic disparity trends in diagnostic imaging, treatments, and survival for non-small cell lung cancer 2007-2016.
Shah M; Parmar A; Chan KKW
Cancer Med; 2020 May; 9(10):3407-3416. PubMed ID: 32196964
[TBL] [Abstract][Full Text] [Related]
3. Randomised phase II study of panitumumab plus irinotecan versus cetuximab plus irinotecan in patients with KRAS wild-type metastatic colorectal cancer refractory to fluoropyrimidine, irinotecan and oxaliplatin (WJOG 6510G).
Sakai D; Taniguchi H; Sugimoto N; Tamura T; Nishina T; Hara H; Esaki T; Denda T; Sakamoto T; Okuda H; Satoh T; Tsushima T; Makiyama A; Tsuda T; Hosokawa A; Kuramochi H; Tokunaga S; Moriwaki T; Yasui H; Ishida H; Tsuji A; Otsu S; Shimokawa H; Baba E; Sato M; Matsumoto S; Ozaki Y; Shinozaki K; Tamagawa H; Goto M; Kadowaki S; Fujii H; Koh Y; Yamazaki K; Hironaka S; Kishimoto J; Boku N; Hyodo I; Muro K
Eur J Cancer; 2020 Aug; 135():11-21. PubMed ID: 32526634
[TBL] [Abstract][Full Text] [Related]
4. Associations among socioeconomic status, patterns of care and outcomes in breast cancer patients in a universal health care system: Ontario's experience.
Kumachev A; Trudeau ME; Chan KK
Cancer; 2016 Mar; 122(6):893-8. PubMed ID: 26696022
[TBL] [Abstract][Full Text] [Related]
5. Prognostic Impact of R0 Resection and Targeted Therapy for Colorectal Cancer with Synchronous Peritoneal Metastasis.
Shida D; Yoshida T; Tanabe T; Tsukamoto S; Ochiai H; Kanemitsu Y
Ann Surg Oncol; 2018 Jun; 25(6):1646-1653. PubMed ID: 29572704
[TBL] [Abstract][Full Text] [Related]
6. The impact of socioeconomic status on stage of cancer at diagnosis and survival: a population-based study in Ontario, Canada.
Booth CM; Li G; Zhang-Salomons J; Mackillop WJ
Cancer; 2010 Sep; 116(17):4160-7. PubMed ID: 20681012
[TBL] [Abstract][Full Text] [Related]
7. Continuation of Bevacizumab vs Cetuximab Plus Chemotherapy After First Progression in KRAS Wild-Type Metastatic Colorectal Cancer: The UNICANCER PRODIGE18 Randomized Clinical Trial.
Bennouna J; Hiret S; Bertaut A; Bouché O; Deplanque G; Borel C; François E; Conroy T; Ghiringhelli F; des Guetz G; Seitz JF; Artru P; Hebbar M; Stanbury T; Denis MG; Adenis A; Borg C
JAMA Oncol; 2019 Jan; 5(1):83-90. PubMed ID: 30422156
[TBL] [Abstract][Full Text] [Related]
8. Effects of socioeconomic status on esophageal adenocarcinoma stage at diagnosis, receipt of treatment, and survival: A population-based cohort study.
Thein HH; Anyiwe K; Jembere N; Yu B; De P; Earle CC
PLoS One; 2017; 12(10):e0186350. PubMed ID: 29020052
[TBL] [Abstract][Full Text] [Related]
9. Comparison of Panitumumab Plus Irinotecan and Cetuximab Plus Irinotecan for KRAS Wild-type Metastatic Colorectal Cancer.
Yamaguchi T; Iwasa S; Nagashima K; Ikezawa N; Hamaguchi T; Shoji H; Honma Y; Takashima A; Okita N; Kato K; Yamada Y; Shimada Y
Anticancer Res; 2016 Jul; 36(7):3531-6. PubMed ID: 27354619
[TBL] [Abstract][Full Text] [Related]
10. Outcome of chemotherapy with or without targeted agents in metastatic colorectal cancer patients with deficient DNA mismatch repair: A single center, cohort study.
Yu Y; Ying J; Zhang W; Li W; Sun Y; Yang L; Cui C; Zeng Y; Zhou A
Asia Pac J Clin Oncol; 2019 Jun; 15(3):128-135. PubMed ID: 30693649
[TBL] [Abstract][Full Text] [Related]
11. Peritoneal carcinomatosis index predicts survival in colorectal patients undergoing HIPEC using oxaliplatin: a retrospective single-arm cohort study.
Burnett A; Lecompte MA; Trabulsi N; Dubé P; Gervais MK; Trilling B; Cloutier AS; Sideris L
World J Surg Oncol; 2019 May; 17(1):83. PubMed ID: 31092250
[TBL] [Abstract][Full Text] [Related]
12. Panitumumab Provides Better Survival Outcomes Compared to Cetuximab for Metastatic Colorectal Cancer Patients Treated with Prior Bevacizumab within 6 Months.
Hayashi K; Mitani S; Taniguchi H; Yasui H; Muro K; Mori K; Gotoda T; Yamazaki K
Oncology; 2019; 96(3):132-139. PubMed ID: 30359979
[TBL] [Abstract][Full Text] [Related]
13. A Prospective, Multicenter Phase II Study of the Efficacy and Feasibility of 15-minute Panitumumab Infusion Plus Irinotecan for Oxaliplatin- and Irinotecan-refractory, KRAS Wild-type Metastatic Colorectal Cancer (Short Infusion of Panitumumab Trial).
Akiyoshi K; Hamaguchi T; Yoshimura K; Takahashi N; Honma Y; Iwasa S; Takashima A; Kato K; Yamada Y; Onodera H; Takeshita S; Yasui H; Sakai G; Akatsuka S; Ogawa K; Horita Y; Nagai Y; Shimada Y
Clin Colorectal Cancer; 2018 Mar; 17(1):e83-e89. PubMed ID: 29169974
[TBL] [Abstract][Full Text] [Related]
14. The impact of socioeconomic status on survival in stage III colon cancer patients: A retrospective cohort study using the SEER census-tract dataset.
Dhahri A; Kaplan J; Naqvi SMH; Brownstein NC; Ntiri SO; Imanirad I; Felder SI; Dineen SP; Sanchez J; Dessureault S; Carballido E; Powers BD
Cancer Med; 2021 Aug; 10(16):5643-5652. PubMed ID: 34197047
[TBL] [Abstract][Full Text] [Related]
15. The addition of bevacizumab to fluoropyrimidine, irinotecan and oxaliplatin-based therapy improves survival for patients with metastatic colorectal cancer (CRC): combined analysis of efficacy.
Popov I; Milicević M; Radosević-Jelić Lj
Acta Chir Iugosl; 2008; 55(4):11-6. PubMed ID: 19245134
[TBL] [Abstract][Full Text] [Related]
16. The Association between Income Status and Treatment Selection for Prostate Cancer in a Universal Health Care System: A Population-Based Analysis.
Oake JD; Harasemiw O; Tangri N; Ferguson TW; Saranchuk JW; Bansal RK; Drachenberg DE; Nayak JG
J Urol; 2021 Nov; 206(5):1204-1211. PubMed ID: 34181467
[TBL] [Abstract][Full Text] [Related]
17. Beyond the dollar: Influence of sociodemographic marginalization on surgical resection, adjuvant therapy, and survival in patients with pancreatic cancer.
Kagedan DJ; Abraham L; Goyert N; Li Q; Paszat LF; Kiss A; Earle CC; Mittmann N; Coburn NG
Cancer; 2016 Oct; 122(20):3175-3182. PubMed ID: 27391466
[TBL] [Abstract][Full Text] [Related]
18. Impact of travel distance on access to treatment and survival in patients with metastatic colorectal cancer prescribed bevacizumab plus chemotherapy.
Payette E; Sarker S; Chalchal H
Can J Rural Med; 2017; 22(4):148-152. PubMed ID: 28925914
[TBL] [Abstract][Full Text] [Related]
19. Differential histopathologic parameters in colorectal cancer liver metastases resected after triplets plus bevacizumab or cetuximab: a pooled analysis of five prospective trials.
Cremolini C; Milione M; Marmorino F; Morano F; Zucchelli G; Mennitto A; Prisciandaro M; Lonardi S; Pellegrinelli A; Rossini D; Bergamo F; Aprile G; Urbani L; Morelli L; Schirripa M; Cardellino GG; Fassan M; Fontanini G; de Braud F; Mazzaferro V; Falcone A; Pietrantonio F
Br J Cancer; 2018 Apr; 118(7):955-965. PubMed ID: 29531324
[TBL] [Abstract][Full Text] [Related]
20. Comparing Late-line Treatment Sequence of Regorafenib and Reduced-intensity FOLFOXIRI for Refractory Metastatic Colorectal Cancer.
Tai CC; Chen WS; Jiang JK; Yang SH; Wang HS; Chang SC; Lan YT; Lin CC; Lin HH; Huang SC; Cheng HH; Chao Y; Teng HW
Am J Clin Oncol; 2020 Jan; 43(1):28-34. PubMed ID: 31693507
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
